Navigation Links
Experts Highlight New Tool as a Timely Addition to Asthma Treatment
Date:12/10/2008

MENLO PARK, Calif., Dec. 10 /PRNewswire/ -- As part of the broader public discussion around asthma sparked by the FDA's examination of the commonly prescribed asthma drugs Advair, Symbicort, Serevent and Foradil, Dr. Philip Marcus, Chief, Division of Pulmonary Medicine, St. Francis Hospital, and Dr. James Wolfe, of Allergist, Allergy and Asthma Associates of Northern California, are available to discuss exhaled nitric oxide monitoring as an essential addition to asthma treatment, specifically as it regards the proper prescription of inhaled corticosteroids for asthma management.

Contact: Michael Krems of EVC Group, (805) 496-8166 or mkrems@evcgroup.com.

A public discussion of the proper treatment of asthma has been prompted by recently released analysis by the FDA of four drugs used to treat asthma that may be linked to asthma related deaths and other adverse events. Patients and the families of patients may turn their attention at this time to the broader issues regarding asthma treatment, especially for children. Drs. Marcus and Wolfe are available to discuss these issues, especially as they regard the value and importance of exhaled nitric oxide, a non-invasive marker of airway inflammation that can guide the more precise prescription of corticosteroids for asthma management.

Dr. James Wolfe, Allergist, Allergy and Asthma Associates of Santa Clara Valley, San Jose, CA says:

"Combination drug therapy with an inhaled corticosteroid (ICS) and a long-acting beta agonist (LABA) has been mainstay of asthma therapy during the last decade. Recent concern raised by the FDA has the potential to affect the prescribing habits of physicians who may elect to utilize a LABA with an ICS preparation. In view of the potential change in the landscape of therapy for bronchial asthma, measurement of the level of inflammation using an eNO monitoring may have an even greater role in guiding the dose of ICS therapy for asthma. Measurement of eNO level has been shown to be helpful in determining an effective and appropriate dose of ICS preparation, thereby avoiding both under-treatment and over-treatment with ICS."

Dr. Philip Marcus, Chief, Division of Pulmonary Medicine at St. Francis Hospital, Roslyn, NY, says:

"The challenge for physicians who treat patients with asthma is to provide the best possible control with the lowest level of medication. Exhaled nitric oxide (eNO) provides an accurate measurement of airway inflammation which enables a more targeted corticosteroid prescription. This empowers physicians to decide the right treatment regimen for the right patient. In addition to Asthma Control Test (ACT) and pulmonary function testing, eNO appears to add another dimension in treating asthma and improving overall asthma control."

About Apieron

Apieron Inc. is a private, venture-backed medical device company based in Menlo Park, CA that was formed in early 2001 to develop a simple-to-use, non- invasive monitor for the measurement of exhaled nitric oxide (eNO) for the management of asthma. The Apieron biosensor technology platform utilizes a patented technology that allows for the highly sensitive detection of selected analytes like eNO. Apieron is committed to collaborating with physicians and patients to develop innovative medical solutions to improve quality of life and standards of care.


'/>"/>
SOURCE Apieron Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Research Links TV/Video Game Playing With Child Obesity; Health Experts Back a New Approach
2. MultiVu Video Feed: PUBLIC HEALTH EXPERTS CONVENE TO DISCUSS THE TREATMENT AND PREVENTION OF RABIES
3. Health IT Event Draws Experts to the Pacific Northwest
4. Experts Sort Out Good Fats From Bad
5. Experts Offer Tips on Lung Cancer Prevention
6. March of Dimes, Experts for Moms and Babies, Launches Podcast
7. World fertility experts to meet in Montreal - IVF and IVM patients to provide first-person accounts at 14th World Congress
8. Bay IVF Experts Launch One of First East-West Fertility Programs of Its Kind
9. Experts propose cholesterol tests at 15 months of age
10. Experts Publish New Lung Disease Guidelines
11. Experts, Advocates Available to Comment on Hillary Clintons Health Care Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... , ... The Texas Cord Blood Bank (TCBB), a program of nonprofit biomedical ... Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in collecting umbilical cord ... donate. , “Women’s Hospital at Renaissance has been a collection partner for the ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... People are ... older people. “Wearing a hearing aid doesn’t have the stigma it had when great-grandpa ... Hearing Associates of Greater Boston, in a NALA North American Speaker Series ...
(Date:4/28/2017)... ... 2017 , ... Researchers at Moffitt Cancer Center ... Data Hub in a sample of participants enrolled in an ongoing cancer quality-of-life ... solutions for the global scientific community. The company’s new CentrePoint Data Hub is ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation Limited, a ... its Nova Skin Sciences division, recently announced the launch of Allumière Antiaging Cream, ... power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark Extract and ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... anniversary. SearchLight is the premier online modeling resource for fluorescence microscopists and optical ... active users during last 5 years spanning the globe, SearchLight has become a ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... -- Cardiology devices segment is anticipated to reach the highest ... Devices segment is likely to create absolute $ opportunity of ... 2017. By the end of 2027, Cardiology Devices segment is ... Mn, expanding at a CAGR of 18.4% over the forecast ... Pacific reprocessed medical devices market in terms of ...
(Date:4/19/2017)... , Tenn. and DALLAS , April 19, ... Inc., announced that the first patients in ... EndoStim device in the Lower Esophageal Sphincter Stimulation for ... minimally-invasive implantable device designed to provide long-term reflux control ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
Breaking Medicine Technology: